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Abstract
Background
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients
requires special case management. AmBisome monotherapy at 40 mg/kg is recommended
by the World Health Organization. The objective of the study was to assess if a combination
of a lower dose of AmBisome with miltefosine would show acceptable efficacy at the end of
treatment.
Methodology/Principal findings
An open-label, non-comparative randomized trial of AmBisome (30 mg/kg) with miltefosine
(100 mg/day for 28 days), and AmBisome monotherapy (40 mg/kg) was conducted in Ethio-
pian VL patients co-infected with HIV (NCT02011958). A sequential design was used with a
triangular continuation region. The primary outcome was parasite clearance at day 29, after
the first round of treatment. Patients with clinical improvement but without parasite clear-
ance at day 29 received a second round of the allocated treatment. Efficacy was evaluated
again at day 58, after completion of treatment.
Recruitment was stopped after inclusion of 19 and 39 patients in monotherapy and com-
bination arms respectively, as per pre-specified stopping rules. At D29, intention-to-treat
efficacy in the AmBisome arm was 70% (95% CI 45–87%) in the unadjusted analysis, and
50% (95% CI 27–73%) in the adjusted analysis, while in the combination arm, it was 81%
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(95% CI 67–90%) and 67% (95% CI 48–82%) respectively. At D58, the adjusted efficacy
was 55% (95% CI 32–78%) in the monotherapy arm, and 88% (95% CI 79–98%) in the com-
bination arm.
No major safety concerns related to the study medication were identified. Ten SAEs
were observed within the treatment period, and 4 deaths unrelated to the study medication.
Conclusions/Significance
The extended treatment strategy with the combination regimen showed the highest docu-
mented efficacy in HIV-VL patients; these results support a recommendation of this regimen
as first-line treatment strategy for HIV-VL patients in eastern Africa.
Trial registration number
www.clinicaltrials.gov NCT02011958.
Author summary
Visceral Leishmaniasis is a complex parasitological disease and is particularly challenging
to treat in patients coinfected with human immunodeficiency virus (HIV). Antimonial
drugs used in first-line treatments for immunocompetent patients in eastern Africa are
more toxic in immunocompromised patients. In 2010, a WHO expert committee recom-
mended a lipid formulation of amphotericin B as first line treatment for HIV/VL co-
infected patients, based on a single clinical trial conducted in Spain and empirical infor-
mation obtained from scattered case reports using AmBisome (liposomal amphotericin
B). In addition, Me´decins Sans Frontières began a compassionate use regimen combining
AmBisome and miltefosine a in a treatment centre in Northwest Ethiopia with encourag-
ing results. Here, we report the results of a trial to assess the efficacy and safety of both the
currently internationally recommended treatment of AmBisome monotherapy and the
new AmBisome-miltefosine combination regimen, in Ethiopian patients. The results of
this trial show that one course of treatment with either regimen could be insufficient to
clear parasites in a high proportion of patients and that an extended treatment strategy, of
administrating a second course of treatment, could lead to a high parasite clearance rate
in patients treated with the combination regimen.
Introduction
Human immunodeficiency virus (HIV) affects visceral leishmaniasis (VL) by increasing its
incidence, altering its clinical manifestation and severity, and, more importantly, by worsening
treatment outcomes and relapse rates [1,2]. VL is the second most deadly protozoan infection
after malaria. HIV-VL co-infection has been observed in at least 35 countries on four conti-
nents [3–6]. Following the introduction of highly active anti-retroviral therapy (HAART), the
incidence of VL in HIV patients has decreased in most settings [7]. Northwest Ethiopia has the
highest burden globally, with HIV rates among VL patients ranging between 20–40% [2,3].
Typically, young male seasonal workers migrate to the lowlands to harvest crops, sleep in
improvised shelters, and are exposed to the bites of sand flies. In addition, migrant workers are
at high risk of HIV infection [2,8,9].
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The current WHO recommended regimen is infusion of amphotericin B lipid formulations
3–5 mg/kg daily or intermittently up to a total dose of 40 mg/kg [10], despite the absence of
proper evaluation in most endemic areas. The Ethiopian National Guidelines (2013) [11] rec-
ommend liposomal amphotericin B and sodium stibogluconate (SSG) as the first and second
line treatments for HIV-VL patients. While effectiveness studies at 40 mg/kg AmBisome are
lacking, effectiveness at 30 mg/kg was less than 60% among HIV co-infected patients [12]. SSG
has poor effectiveness (43%–70%) and considerable toxicity, with an increased risk of death in
HIV co-infected patients [13,14]. Thus, there is an urgent need for a better treatment approach
to VL in HIV co-infected patients.
Preventing recurrence of disease is another important factor, as relapse cases are even more
difficult to cure, consequently becoming reservoirs of the parasite and playing a role in trans-
mission [15]. Negative aspirate after treatment is the best predictor of absent/delayed relapse.
Surviving HIV patients develop some tolerance to the parasite. The annual VL relapse rate
among HAART-taking HIV patients in Northwest Ethiopia was more than 60% if their CD4
count was less than 100 cells/μl [16]. A recent cohort study in Northwest Ethiopia demon-
strated 71% disease-free survival one year after VL treatment using pentamidine as secondary
prophylaxis [17].
This clinical trial was conducted primarily to evaluate the day 29 efficacy of a combination
of AmBisome (30 mg/kg) with miltefosine (100 mg/day for 28 days) and AmBisome mono-
therapy (40 mg/kg) for VL in HIV co-infected patients in Northwest Ethiopia. Secondary
objectives were to assess efficacy at day 58 and the safety of the regimens. A long-term evalua-
tion of relapse-free survival up to one-year follow-up (Day 390), including an estimate of the
relapse rate in those receiving pentamidine as a prophylactic treatment, will be reported in
another publication.
Methods
Ethics statement
This study was conducted according to principles of the Helsinki declaration, Good Clinical
Practice (GCP) rules, and local regulations. The Protocol and the Informed Consent Sheet
were revised and approved by the University of Gondar Institutional Review Board, the Ethio-
pian National Research Ethics Review Committee, the Me´decins Sans Frontières Ethics Review
Board, the London School of Hygiene and Tropical Medicine Research Ethics Committee, the
Antwerp University Hospital Ethics Committee, and the Prince Leopold Institute of Tropical
Medicine Institutional Review Board. Approval from the Food, Medicine and Healthcare
Administration and the Control Authority of Ethiopia was also obtained before inclusion of
the patients. Patients were included after completion of a written informed consent process.
Study design
This study, registered on www.clinicaltrials.gov (NCT02011958), included two components.
The first component was a non-comparative randomized open-label clinical trial to evaluate
the end of treatment efficacy and safety of two treatment regimens for VL in HIV co-infected
patients (Fig 1). This component used a sequential design, in which the sample size is not fixed
in advance but depends on the accruing endpoint data. More specifically, we used a triangular
continuation region which is a graphical representation of the stopping rules of the trial
[18,19] (Fig 2). The results cannot easily be interpreted without reference to the graphical
representation. The trial design allows for regular interim analyses, and hence possible stop-
ping, after every 10 patients, based on acceptable or unacceptable efficacy values set in the pro-
tocol. This design allows recruitment to be stopped as patients are being evaluated if the
AmBisome alone and combined with miltefosine for visceral leishmaniasis in HIV patients
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observed efficacy is too low (lack of promise), i.e. crossing the lower boundary of the triangular
region (pink area), or sufficiently high (promise), i.e. crossing the upper boundary (blue area).
Otherwise recruitment continues, corresponding to the interior of the triangular continuation
region in the graphical representation (green area). In more technical terms, the null hypothe-
sis was that the proportion of patients reaching negative parasitology at day 29 (p) is less than
or equal to a value p0, which we set to 75%. A test statistic falling outside the continuation
region in the graphical representation would lead to a decision to stop recruitment. If the
upper boundary is crossed during an interim analysis, then the null hypothesis is rejected and
we conclude that p>75%. Crossing the lower boundary implies that the null hypothesis (pro-
portion reaching negative parasitology�75%) is not rejected and there is a specified power to
exclude a proportion reaching negative parasitology of pa, for which we chose a value of 90%.
Less formally, on crossing the upper boundary, the trial should be stopped for promise (effi-
cacy above 75%), and on crossing the lower boundary it should be stopped for lack of promise
(efficacy below 90%). The type I error rate and power of the study were pre-specified as 5%
and 95%, respectively (α = β = 0�05). Interim analyses were specified after every 10 patients in
each arm had reached the Day 29 endpoint. An independent Data Safety Monitoring Board
(DSMB) evaluated the results and confirmed decisions to continue or stop with recruitment in
each arm. Based on the sequential trial design and the parameters described above, the
Fig 1. Treatment strategy.
https://doi.org/10.1371/journal.pntd.0006988.g001
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maximum sample size per arm was 66. The second component included a follow-up for 12
months with secondary prophylaxis for severely immunocompromised patients. Results will
be described in a separate publication.
Patients were recruited at two facilities in Ethiopia, the Leishmaniasis Research and Treat-
ment Centre, located within the teaching hospital of the University of Gondar, and the Abdur-
afi Health Centre, located in a rural setting on the border with Sudan and supported by
Me´decins Sans Frontières. These two sites are the main VL treatment centers in Ethiopia. On
average 400 and 800 VL patients are managed every year respectively at these two centers.
Participants
Patients were diagnosed for VL and for HIV as per the Ethiopian national guidelines [11].
Upon presentation of clinical signs and symptoms of VL (e.g. irregular fever for more than 2
weeks, hepatomegaly and/or splenomegaly, weight loss), the patients were diagnosed by identi-
fication of the Leishmania parasite by microscopy in tissue aspirate (spleen aspirate was the
preferred methodology, or bone marrow aspirate in case of contra-indication e.g. bleeding ten-
dency, platelets below 40,000/mm3, haemoglobin below 5 g/dL). Patients were eligible
Fig 2. Sequential analysis. The vertical axis, (Z), is the number of observed treatment successes minus the number of
expected successes. The higher the value represented on that vertical axis, the more favorable (better efficacy observed).
The horizontal axis (V) is proportional to the number of patients who, over time, have been evaluated at day 29. Hence,
over time, each arm’s data points extend to the right. Each arm starts inside the triangle (green area) and recruitment is
stopped on crossing either the upper (blue area) or the lower boundary (pink area). Recruitment to the AmBisome
monotherapy arm was stopped after the first interim analysis (I1) and to the combination arm after the second interim
analysis (I2). Also shown are the final results for each arm, including those who had not reached the primary endpoint
(day29) when the interim analysis was performed and the recruitment was stopped. These final results take the
trajectory of each arm well away from the triangular boundary, which is known as ‘over-run’. The two numbers after
each label are the numbers of patients included in that analysis and the number of these with treatment success at day
29.
https://doi.org/10.1371/journal.pntd.0006988.g002
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regardless of whether this was the first episode of VL (primary case) or whether it was a relapse
case with single or multiple relapses. The parasite strains were not identified, but according to
epidemiological reports [20,21], the circulating parasite causing visceral leishmaniasis in Ethi-
opia is Leishmania donovani. HIV status is routinely determined by two rapid tests followed
by a third confirmatory test in case of discrepancy. Within the trial, it was reconfirmed using
an enzyme immunoassay (ImmunoComb II HIV 1&2 BiSpot, Orgenics Ltd.).
Randomization and masking
Subjects were allocated to treatment using random block sizes, stratified by site (Gondar &
Abdurafi) and by patient type (whether the VL episode at screening was a primary or relapse
case).
The randomization list was prepared by the data management team. Site investigators were
blinded to block sizes. Randomization codes were prepared in sealed, sequentially numbered,
opaque envelopes and were under the control of the site investigator.
Patients and treating physicians were not masked to study treatment due to the consider-
able differences in the administration of the treatment arms (different dosing schedule of an
infused treatment plus oral administration).
Procedures
Patients received in-patient treatment. Liposomal amphotericin B (AmBisome, Gilead Inc.)
was stored and reconstituted as per the manufacturer’s recommendations. In the monotherapy
arm, a dose of 40 mg/kg total dose of AmBisome (adapted from WHO recommendations) was
administered by intra-venous (IV) slow infusion of 5 mg/kg on days 1 to 5, 10, 17, and 24.
In the combination arm, a 30 mg/kg total dose of AmBisome was administered according
to the following schedule: IV slow infusion of 5 mg/kg on days 1, 3, 5, 7, 9, and 11; with a milte-
fosine (Paladin Therapeutics, Inc.) 50 mg capsule orally twice a day for 28 days (all patients
included were above 25 kg).
For both arms, a pre-testing dose of 1 mg of AmBisome was administered to patients before
treatment to rule out allergic reactions, as recommended in the AmBisome Summary of Prod-
uct Characteristics.
An initial assessment of cure was conducted at D29, through clinical and parasitological
examination (spleen or bone marrow aspiration). Patients with negative parasitology were
considered cured of VL and started the follow-up period (Fig 1). Patients who had clinically
improved but still had detectable parasites at D29 were given extended treatment using the
same regimen to which they had been randomized. Patients with detectable parasites at D29,
and who were clinically unwell, and patients with parasites at D58 were given a rescue medica-
tion of the clinician’s choice (Fig 1).
Once the patients had a negative parasitology result, they started a follow-up period of one
year (up to D390) to assess long-term relapse-free survival and safety (not reported here).
Outcomes
The primary endpoint was parasitological clearance at day 29 (D29), which was defined as
absence of parasites in tissue aspirate at D29 (bone marrow or spleen, with spleen aspirate as
the preferred option). Treatment failure at D29 was defined as presence of parasites at the D29
assessment, or death prior to the D29 assessment, or no clinical response to treatment requir-
ing rescue medication on or before D29.
A secondary endpoint to assess treatment outcome after extended treatment was defined as
efficacy at day 58 (D58). D58 treatment success was defined as: (i) being parasite free at D29
AmBisome alone and combined with miltefosine for visceral leishmaniasis in HIV patients
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and no recurrence of symptoms by D58 or (ii) being parasite free at D58 after extended treat-
ment. Thus, D58 failures were patients who (i) received rescue treatment prior to, or at, the
D58 visit, or (ii) were confirmed to be parasite positive at D58 or (iii) died up to D58. A patient
with detectable parasites at D29 who then received extended treatment would be a treatment
failure at D29 but a success at D58 if no parasites were detected at D58.
All adverse events (AEs) and serious adverse events (SAEs) were captured up to one month
after the last dose of study medication (D58 if patients received one round of treatment or D86
if patients received a second round). Grading of the severity of the events was based on Com-
mon Terminology Criteria for Adverse Events (CTCAE), Version 4.0 [22].
Safety laboratory assessments were performed at baseline, D3, D10, D29, and D58, and dur-
ing follow-up as needed. CD4 count was measured at baseline, on D29, and within one month
of reaching negative parasitology. HIV viral load was measured at baseline and every 6 months
as per routine practice, samples were sent to central regional or national reference laboratories.
Results of the viral load were often not available in time to support HIV case management.
Statistical analysis
Data capture and management utilized OpenClinica and Stata software [23]. Data analysis was
performed using Stata, version 14.
The intention to treat (ITT) population was pre-specified as primary analysis population for
the sequential interim analyses of treatment success at D29. Both ITT and per-protocol (PP)
populations for treatment success at D29 and D58 were used for final analyses of treatment
success at D29 and D58. ITT was considered primary analysis population. Interim analyses
took place each time 10 patients per arm had reached the D29 primary endpoint assessment.
Decision making was based on the position of the test statistic relative to the triangular contin-
uation region, as described above [18]. Recruitment and randomization of new patients were
not stopped during interim analysis, but were stopped on the recommendation of the DSMB
when the interim analysis showed that the boundary of the continuation region had been
crossed.
In a sequential trial, recruitment is stopped when a pre-specified difference is reached in
the accruing data. In the current trial, this difference is between the observed and expected
numbers of treatment successes. Stopping when a difference of interest has been achieved
implies a risk that the final results are a “random high” [24]. In other words, the results will
tend to be more extreme than if the sample size had been fixed in advance. To allow for this,
specific analysis methods are required. In particular, simple maximum likelihood estimates—
which in the current trial would be simple proportions—in general suffer from ‘substantial
bias’ [25], in sequential trials. Here, the pre-specified approach, taking into account the
sequential design, was to use point and interval estimates of efficacy obtained at D29, as per
Whitehead [26]. Because this approach assumes that the final data lie close to the boundary of
the continuation region (Fig 2), an additional post-hoc analysis, as per Liu et al. [27], was done
of D29 efficacy to allow for this and for ‘over-run’, i.e. inclusion, in the final analysis, of people
who had been randomized to the trial before the final interim analysis, but whose D29 data
were not then available for inclusion.
The sequential stopping rule applied only as far as the primary outcome at D29. Hence, the
D58 outcome is subject to a mixture of sequential and classical follow-up. To take this into
account, the probability of treatment success at D58 was estimated by a probability tree
method previously developed for this purpose [28].
All adverse events were coded according to Medical Dictionary for Regulatory Activities
(MedDRA, Version 14.0). Safety outcomes were the number (%) of patients experiencing a
AmBisome alone and combined with miltefosine for visceral leishmaniasis in HIV patients
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serious adverse event (SAE) at any time during the trial or follow-up, the number (%) of
patients experiencing an adverse event (AE) between Day 1 of initial treatment and up to one
month after completing treatment, and the incidence of adverse drug reactions (ADRs) by pre-
ferred MedDRA term estimated as the number (%) of patients experiencing at least one ADR
for each MedDRA lower level preferred term. We also report the rate of ADR accounting for
time at risk based on the number of rounds of treatment.
CD4 counts were compared between time points by paired t test.
Results
Patients were recruited between 14 August 2014 and 18 August 2015. Out of the 536 parasito-
logically confirmed VL patients (Fig 3), 81 were HIV positive according to the Ethiopian
national HIV testing algorithm and confirmatory test and 59 patients were enrolled.
Both arms had a similar distribution of baseline characteristics, including body mass index,
VL status, CD4 count, and prior antiretroviral treatment (Tables 1 and 2).
Prior to D29 there were no protocol deviations, thus the ITT populations were identical to
the PP. At D58, the PP population excluded 5 patients with major protocol deviations (Fig 3).
There were no missing outcome data. One patient died after randomization before receiving
any treatment and was excluded from all analyses.
In interim analyses, both arms crossed the lower side of the boundary (Fig 2), indicating
treatment success of less than 90% at D29. The AmBisome monotherapy crossed first, based
on data from 10 patients, and the combination arm crossed the boundary based on data from
20 patients.
In the AmBisome arm, there were only 7 treatment successes out of 19 subjects in the final
data. Stopping in this way, for a difference of a given magnitude, is characteristic of a sequen-
tial trial and required particular statistical methods, as explained above. This pre-specified
analysis gives an estimated efficacy of 70% (95% CI 45–87%) at D29 in the AmBisome arm.
However, this does not take account of the substantial over-run to the lower side of the bound-
ary, visible in Fig 2 (see the Fig 2 legend for an explanation of over-run). After accounting for
this, the estimated efficacy was lower, at 50% (27–73%). In the combination arm, the estimated
success rate is 81% from the pre-specified efficacy analysis (67–90%), and with an adjusted effi-
cacy of 67% (48–82%), taking account of over-run (Table 3).
Efficacy was also estimated at Day 58 (Table 3) to evaluate the success of the extended treat-
ment strategy. Using the over-run adjusted D29 analysis as inputs, the D58 ITT efficacy was
55% (95% CI 32–78%) in the monotherapy arm, and the PP efficacy was 59% (35–83%). The
same analysis in the combination arm gave 88% (79–98%) and 91% (81–100%) for ITT and PP
respectively. These D58 efficacy estimates are higher than those at D29 because improvement
in status between these two time points was more likely than deterioration, thanks to pro-
longation of the treatment. If the over-run phenomenon is not considered, D58 efficacy esti-
mates are slightly higher in both arms, as was the case for D29 (Table 3).
All patients experienced at least one AE (Table 4). A higher percentage of patients experi-
enced at least one ADR in the combination arm than in the monotherapy arm. However, the
rate of ADR was similar between arms, after accounting for time-at-risk for those receiving
one or two rounds of treatment (Table 5). AEs and ADRs were mostly mild or moderate.
ADRs occurring in more than 10% of patients were dyspepsia, gastritis, vomiting mainly
related to miltefosine, increased blood creatinine, and hypokalaemia related to AmBisome.
Two hypokalaemia events (one per arm) were severe in intensity as per CTCAE [22] criteria
(between 2�5 and 3 mmol/L) and required supplementation. All ADRs were considered
expected as per the reference documentation for each drug [29,30]. Ten SAEs were reported
AmBisome alone and combined with miltefosine for visceral leishmaniasis in HIV patients
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during the treatment phase (Table 6), including four deaths, mostly due to infectious events
(sepsis, strongyloidiasis hyperinfection syndrome, meningitis/encephalitis due either to toxo-
plasma or tuberculosis). One patient died from pancreatitis/renal failure related to rescue
treatment with sodium stibogluconate and paromomycin, along with ARV drugs, a combina-
tion known to be toxic in HIV-VL co-infected patients [14].
At admission, approximately 70% of patients were on antiretroviral treatment; overall and
by arm. The tenofovir-lamivudine-efavirenz combination, the first line treatment according to
Ethiopian guidelines, was the most common ARV drug combination used. Only two patients
were receiving a protease inhibitor based regimen. All newly diagnosed HIV patients started
the ARV treatment after completion of the VL treatment, except for one refusal. Three patients
changed their ARV regimen during the VL treatment. CD4 recovery was substantial at the end
of VL treatment compared to baseline, 23 patients presented with CD4 count above 200 cells/
Fig 3. Trial participant flow.
https://doi.org/10.1371/journal.pntd.0006988.g003
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μl compared to only one at baseline (Fig 4A and 4B). In the monotherapy arm, the average
increase in CD4 from baseline to day 29 was 52 cells/μl (95% CI 24–79, paired t-test p = 0�001)
and in the combination arm 111 cells/μl (95% CI 67–155 paired t-test p<0�001). HIV viral
load was available for 55 patients at baseline (Table 2). Only 16 patients had undetectable viral
load among the 41 already receiving ART treatment at inclusion.
Discussion
The burden of VL in HIV patients and the associated poor treatment outcome with all cur-
rently available medicines underline the urgent need for better treatment approaches. This
trial was therefore designed to evaluate a combination treatment (AmBisome plus miltefosine)
and the current WHO recommended regimen (AmBisome monotherapy), with the aim of
providing better quality evidence for future guidelines. The combination arm showed an
Table 1. Baseline characteristics.
AmBisome AmBisome + miltefosine
Number of patients 19 39
Age (years) mean (SD) 37 (8) 33 (5)
median (range) 38 (27–51) 33 (21–45)
Sex, n (%) Male / Female 19 (100) / 0 (0) 38 (97) / 1 (3)
Patient Type, n (%) Primary / Relapse 8 (44) / 10 (56) 18 (50) / 18 (50)
Site, n (%) Gondar / Abdurafi 10 (53) / 9 (47) 20 (51) / 19 (49)
Spleen sizea (cm): mean (SD) 8�1 (5) 7�3 (3)
median (range) 6 (4–22) 7 (3–15)
Body Mass Index status, n (%) Severely underweight (BMI<15) 0 (0) 5 (13)
Underweight (15�0�BMI�18�4) 12 (63) 25 (64)
Normal (18�5�BMI�24�9) 7 (37) 8 (21)
Overweight (BMI�25) 0 (0) 1 (3)
Type of Tissue aspirate Spleen aspirate 18 36
Bone marrow aspirate 1 3
Parasite countb +4 to +6, n (%) 16 (84) 29 (75)
+1 to +3, n (%) 2 (11) 7 (18)
Haemoglobin (g/dL) mean (SD) 8�8 (2) 8�1 (1�9)
median (range) 9�1 (4�9–12) 8�1 (3�6–12�3)
WBC (x103/μL) mean (SD) 2�2 (0�9) 2 (1�1)
median (range) 2�2 (0�8–4�6) 1�7 (0�4–4�3)
Platelets (x103/μL) mean (SD) 112 (54) 126 (66)
median (range) 95 (50–217) 117 (39–315)
SGOT /AST (U/L) mean (SD) 51 (33) 58 (72)
median (range) 42 (15–119) 38 (21–472)
SGPT /ALT (U/L) mean (SD) 39 (38) 35 (50)
median (range) 24 (3–157) 23 (7–325)
Creatinine (mg/dL) mean (SD) 0�9 (0�2) 1 (0�2)
median (range) 0�9 (0�7–1�3) 1 (0�6–1�4)
Potassium (mmol/L) mean (SD) 3�7 (1) 3�4 (0�8)
median (range) 3�8 (2�3–5�4) 3�5 (2�1–4�9)
CD4 (cells/μL) median (range) 69 (30–121) 54 (33–96)
a Below the costal margin
b Parasite count is not reported for those tested by bone marrow aspiration
https://doi.org/10.1371/journal.pntd.0006988.t001
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efficacy rate of 67% on day 29 and 88% on day 58 with prolonged treatment (ITT). In the PP,
efficacy at D58 reached 91%.
In 2008, Ter Horst and colleagues [16] made 5 recommendations for the management of
VL and HIV co-infected patients in Ethiopia: (i) ART should be provided to all HIV positive
individuals; (ii) VL should be an AIDS-defining illness and a valid entry point to ART, irre-
spective of CD4 count, to reduce the chance of relapse; (iii) secondary prophylaxis is necessary
when the risk of relapse is high; (iv) parasitological clearance is a crucial end point for VL treat-
ment; and (v) combination therapy can minimize the risk of developing resistance. Our study
Table 2. HIV parameters and antiretroviral (ART) regimen at baseline.
AmBisome AmBisome + miltefosine
ART at baseline ART at baseline
No Yes No Yes
Nb of patients 6 13 11 28
CD4 count (cells/μl) <50 2 (33) 6 (46) 6 (55) 11 (39)
50–99 4 (67) 2 (15) 3 (27) 11 (39)
100 to 199 0 (0) 5 (38) 2 (18) 5 (18)
200–349 0 (0) 0 (0) 0 (0) 1 (4)
�350 0 (0) 0 (0) 0 (0) 0 (0)
Median (IQR) 70 (30–77) 50 (44–129) 45 (33–97) 56 (31–96)
Viral Load (copies per ml) <150 –undetectable 0 (0) 7 (54) 0 (0) 9 (32)
150 to <3 log10 0 (0) 3 (23) 0 (0) 4 (14)
�3 to <4 log10 0 (0) 0 (0) 0 (0) 2 (7)
�4 to <5 log10 0 (0) 1 (8) 1 (9) 4 (14)
�5 to <6 log10 3 (50) 2 (15) 4 (36) 4 (14)
�6 log10 3 (50) 0 (0) 5 (45) 3 (11)
missing 0 (0) 0 (0) 1 (9) 2 (7)
Median (IQR)1 6.51 log10
(5�68–6�92
log10)
150
(150–926)
5�98 log10
(5�30–6�38
log10)
869
(150–5�26
log10)
1 Values less than detection threshold, or less than 150 copies/ml have been set to 150 copies/ml.
https://doi.org/10.1371/journal.pntd.0006988.t002
Table 3. Efficacy (as per sequential analysis).
AmBisome AmBisome + miltefosine
N Treatment success, n %, 95% CI� N Treatment success, n %, 95% CI�
Cumulative analysis (D29)
ITT & PP [26] 19 7 70 (45–87) 39 22 81 (67–90)
ITT &PP (over run) [27] 19 7 50 (27–73) 39 22 67 (48–82)
Cumulative analysis (D58)
ITT [26] 19 9 68 (44–91) 37 31 93 (87–99)
PP [26] 16 9 70 (46–94) 35 31 95 (90–100)
ITT (over run) [27] 19 9 55 (32–78) 37 31 88 (79–98)
PP (over run) [27] 16 9 59 (35–83) 35 31 91 (82–100)
� The pre-specified analysis approach accounts for features of the trial design and therefore the appropriate point estimate of efficacy is not simply a ratio of the number
of treatment successes to the number randomized.
https://doi.org/10.1371/journal.pntd.0006988.t003
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focuses on an initial effective treatment defined by parasite clearance at the end of VL therapy
(responding to points iv and v), supplemented by secondary prophylaxis and ART (responding
to points ii and iii; manuscript in preparation).
The limited number of study reports available on HIV-VL treatment in the region generally
show poor treatment outcomes with all the available anti-leishmanial drugs. In a previous
study that compared SSG and miltefosine for the treatment of VL, a subgroup analysis showed
cure rates of 90% and 78%, and death rates of 7% and 2% for SSG and miltefosine respectively
[31]. This study included mainly primary VL, and a death rate of 19% was also reported
among patients with unknown HIV status and treated with SSG (patients suspected of
advanced AIDS disease). Subsequent studies evaluating SSG in treatment of HIV-VL co-
infected patients showed a cure rate that ranged from 43% to 70%, and death rates during
treatment that ranged from 14–17% (or ~15%) [2]. AmBisome at a 30 mg/kg dose showed a
cure rate of 60% and failure rate of 32%, with a worse outcome in relapsed cases as compared
to primary HIV-VL co-infected patients [12].
A randomized trial that enrolled 57 HIV-VL patients from Spain, infected with a different
species (Leishmania infantum), compared two regimens of amphotericin B lipid complex
(ABLC 15 mg/kg and 30 mg/kg total dose), with meglumine antimoniate [32]. The initial cure
Table 4. Safety during the treatment phase.
AmBisome AmBisome + miltefosine
N = 19 N = 39
Number (%) of patients with at least one SAE
Total� 2 (10) 8 (21)
Related to study drugs (ADR) 0 (0) 0 (0)
Unrelated to study drugs 2 (10) 8 (21)
Number (%) of patients with at least one AE (whether serious or not)
Total� 19 (100) 39 (100)
Related to study drugs (ADR) 12 (63) 33 (85)
Unrelated to study drugs 18 (95) 33 (85)
Number (%) of patients with at least one ADR (whether serious or not) by intensity
1 Mild 11 (58) 22 (56)
2 Moderate 3 (16) 15 (38)
3 Severe 1 (5) 1 (3)
4 Life-threatening 0 (0) 0 (0)
5 Death 0 (0) 0 (0)
Number of ADRs per patient
Median 1 1
Range 0–5 0–5
Total person days at risk�� 1262 2534
Unadjusted rate per day (95% CI) 0.018
(0.011-0.026)
0.026
(0.019-0.032)
AE = adverse event, SAE = serious adverse event, ADR = adverse drug reaction; Events reported here occurred
during the treatment phase i.e. from day 1 to day 58 for patients with one round of treatment, day 1 to day 86 for
those on extended treatment
� these rows do not necessarily add to the total number of patients because a single patient may have events in
multiple rows
�� Time at risk is from day 1 to day 86 for those on extended treatment, otherwise from day 1 to day 58. For those
who died before these limits, their time at risk was from day 1 until their death.
https://doi.org/10.1371/journal.pntd.0006988.t004
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rates were 33% (95% CI 13%-59%), 42% (95% CI 16%-62%), and 37% (95% CI 16%-62%),
respectively. Treatment with the amphotericin B lipid formulation had fewer safety concerns
and treatment discontinuations. Despite the limited number of patients per arm in this ran-
domized study (18, 20, and 19 respectively), this evidence, together with a number of reported
case series using AmBisome, was used by the WHO Expert Committee to recommend the use
of amphotericin B lipid formulations up to 40mg/kg for the treatment of HIV-VL co-infected
patients with an ‘A’ grade of evidence [10].
The clinical trial described here is the first to evaluate the efficacy of the combined regimen
of AmBisome and 28-day miltefosine. It has demonstrated much higher efficacy in African
HIV-VL co-infected patients than the previous trial in Spain using ABLC monotherapy [32].
This result was obtained when the combination was used within a strategy of extended treat-
ment based on the patient’s initial clinical and parasitological response to treatment. Indeed,
this strategy achieved a parasite clearance rate of 91% at the end of treatment for patients with
high compliance (i.e. per protocol analysis population). Notably, the combination treatment
Table 5. Incidence of ADRs due to AmBisome or miltefosine. Incidence>10% indicated in bold.
Number of patients with ADR, n (%) AmBisome
N = 19
AmBisome + miltefosine
N = 39
Total
N = 58
Possibly related to:
AmBisome Miltefosine Either Total
Gastrointestinal disorders
Abdominal pain 0 (0) 0 (0) 1 (3) 0 (0) 1 (3) 1 (2)
Diarrhoea 1 (5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2)
Dyspepsia 2 (11) 0 (0) 6 (15) 2 (5) 8 (21) 10 (17)
Gastritis 0 (0) 0 (0) 9 (23) 0 (0) 9 (23) 9 (16)
Glossitis 1 (5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2)
Nausea 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 1 (2)
Peptic ulcer 1 (5) 0 (0) 2 (5) 0 (0) 2 (5) 3 (5)
Stomatitis 1 (5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2)
Vomiting 3 (16) 0 (0) 9 (23) 2 (5) 11 (28) 14 (24)
General disorders and administration site conditions
Pain 1 (5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2)
Infections and infestations
Folliculitis 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 1 (2)
Investigations
Blood creatinine increased 5 (26) 10 (26) 0 (0) 1 (3) 11 (28) 16 (28)
Metabolism and nutrition disorders
Hypokalaemia 4 (21) 6 (15) 0 (0) 0 (0) 6 (15) 10 (17)
Musculoskeletal and connective tissue disorders
Back pain 1 (5) 1 (3) 1 (3) 0 (0) 1 (3) 2 (3)
Neck pain 1 (5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2)
Polyarthritis 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 1 (2)
Nervous system disorders
Cluster headache 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 1 (2)
Headache 0 (0) 1 (3) 0 (0) 0 (0) 1 (3) 1 (2)
Skin and subcutaneous tissue disorders
Pruritus 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 1 (2)
Rash papular 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 1 (2)
https://doi.org/10.1371/journal.pntd.0006988.t005
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offers encouraging efficacy in relapse patients with previous history of VL treatment, as they
represent half of the patient population included in the trial.
Table 6. Serious adverse events.
ID MedDRA preferred term Gradea Relation to study drugb Day of onset Outcome
AmBisome monotherapy
303 Sepsis 3 1 3 Resolved
307 Malnutrition 3 1 30 Death
Decubitus ulcer 3 1 38
Pneumonia 4 1 39
Sepsis 5 1 39
AmBisome + miltefosine
112 Anaemia 4 1 48 Resolved
113 Strongyloidiasis 5 1 61� Death
115 Anaemia 4 1 10 Resolved
207 Anaemia 3 1 3 Resolved
408 Post herpetic neuralgia 2 1 10 Resolved
410 Toxicity to various agentsc 5 1 33 Death
411 Encephalitis 5 1 15 Death
Meningitis 5 1 15
415 Pulmonary tuberculosis 3 1 20 Unknown
aMild (grade 1), moderate (grade 2), severe (grade 3), life threatening (grade 4), death (grade 5)
b1 = Not related 2 = Possibly related
c Toxicity was related to sodium stibogluconate and paromomycin administered as rescue treatment and to ART drugs (patient received sequentially zidovudine/
lamivudine/nevirapine and tenofovir/lamivudine/nevirapine)
� This death occurred slightly after the treatment phase recording period but is reported here as first symptoms were reported during the period.
https://doi.org/10.1371/journal.pntd.0006988.t006
Fig 4. CD4-cell counts at baseline (D0), D29 and D58. Categories are Cat 1 =<50, Cat 2 = 50–99, Cat 3 = 100–199, Cat 4 = 200–349, Cat 5 =�350 cells/μl. (A)
AmBisome monotherapy arm (B) AmBisome+miltefosine combination arm.
https://doi.org/10.1371/journal.pntd.0006988.g004
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Importantly, in the context of this trial, we observed the value of parasitological assessment
at the end of treatment, especially for HIV-VL patients, clinical evaluation not being suffi-
ciently sensitive to detect patients who failed to clear parasites after the initial treatment. This
allowed us to demonstrate that prolongation of same treatment can be effective.
In terms of safety, although all patients experienced at least one adverse event, which is to
be expected in this seriously ill population, no AE led to VL treatment discontinuation.
Adverse drug reactions were reported in a significant number of patients, but most events
were of mild intensity, and mostly corresponded to a single episode of vomiting, known to be
associated with miltefosine. Sporadic hypokalaemia remains a concern with AmBisome and
requires close monitoring, as previously reported in India [33]. These data therefore suggest a
satisfactory safety profile in a population with a high burden of concomitant illness and medi-
cation. Prolonging treatment using the extended treatment strategy does not seem to create
any safety concern impacting compliance to treatment, although the number of patients in the
trial was not conducive to detecting rare events.
Although the combination regimen and treatment strategy identified by this randomized
trial shows promising results for the HIV-VL co-infected population, the medicines used
remain very expensive, and quality of HIV care remains a challenge to ensuring long-term
patient survival. VL control programs in the region are mostly dependent on the support of
international organizations that should consider HIV-VL patients as fully part of their main
target, despite the financial burden that they represent. Indeed, since HIV-VL co-infected
patients are chronically infected, frequently suffer relapse episodes (with high parasitaemia),
and can infect sand flies [15], they act as a reservoir in the population. Implementation of a
regimen that enhances parasite clearance is thus of major importance both for the individual
patient and at the public health level to reduce circulation of the parasite in the community.
Ensuring access and optimal care for these patients could impact the efficacy of elimination
programmes such as the Indian Kala-azar Elimination Program.
Considering both individual and public health benefits, there is a strong case for the prompt
adoption of this strategy into national and regional African guidelines. The Ethiopian authori-
ties have committed to rapidly endorsing the AmBisome and miltefosine combination as the
first line regimen in their national treatment guidelines for HIV-VL co-infected patients.
Because both arms crossed the triangular boundary on the lower side, corresponding to a
lack of promise, defined as an efficacy of less than 90%, this can be considered as a limitation
to the study. This 90% parameter was arguably set too high for this patient population, because
efficacy values, for example, in the range 80–90% are still higher than observed in previous
studies in HIV-VL patients. Moreover, the data over ran the triangular boundary by a large
amount, while the primary analysis assumes this to be negligible. It was therefore felt necessary
to take this into account in an additional analysis which is given prominence in the current
report. Because of the scarcity of suitable clinical trial sites accessible to patients from remote
areas and providing sufficient level of security and stability, the trial was not designed or pow-
ered for a comparison of efficacy between arms. However, there is no overlap between 95%
CIs around the ITT efficacy at D58 accounting for over-run, tending to suggest higher D58
efficacy in the combination arm.
The numbers of HIV-VL co-infected patients seems to be decreasing in Ethiopia, probably
due to the implementation of prevention strategies and large scale anti-retroviral treatment
programs. However, some gaps remain in identifying patients with low compliance to HIV
treatment, leading to ART failure and emergence of viral resistance, with a consequently late
switch to second line ARV treatment. HIV viral load services are limited and results are
reported only after long delays. Suboptimal HIV treatment might result in re-emergence of VL
cases. This study was not designed to evaluate the importance of ART regimen on the efficacy
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and sustainability of the response to VL treatment. Closer monitoring of the evolution of CD4,
cytokine profile, and HIV viral load would have allowed for a better understanding of the
pathophysiology of co-infection, but this was not possible in the clinical settings where the
trial was conducted.
In terms of generalizability, geographic variation in efficacy is observed with the commonly
used anti-leishmanial medicines, in particular between Africa and India. This study was con-
ducted in Northwest Ethiopia where, as in Sudan, L. donovani has high strain diversity and is
often difficult to treat. These results, even if encouraging, cannot be extrapolated to other set-
tings without reservation. Experience shows that in the Indian subcontinent patients usually
respond to lower doses of treatment compared to in Africa. A retrospective study conducted
in India with a similar combination regimen (same dose of AmBisome (30 mg/kg) but 14
instead of 28 days of miltefosine) suggested this regimen would be safe, effective, and tolerable
[34]. There is now an ongoing randomized trial in India to evaluate this regimen (CTRI/2015/
05/005807). In Europe and Brazil, which share the same parasite L. infantum, differences in
the circulating parasites would probably justify bridging studies.
In conclusion, the results of this randomized trial strongly support a change in the treat-
ment recommendations for HIV-VL co-infected patients, from AmBisome monotherapy to
combination therapy as the first line treatment. A new case management strategy where dura-
tion of treatment is dependent on reaching a negative parasitology, by using one or two rounds
of treatment, should be adopted. AmBisome-miltefosine combination therapy has a satisfac-
tory safety profile and is highly efficacious.
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